Author's response to reviews

Title: Evaluation of an early step-down strategy from IV anidulafungin to oral azole therapy for the treatment of candidemia and other forms of invasive candidiasis: results from an open-label trial

Authors:

Jose Vazquez (jvazquez@gru.edu)
Annette C. Reboli (reboli@rowan.edu)
Peter G. Pappas (pappas@uab.edu)
Thomas F. Patterson (Patterson@uthscsa.edu)
John Reinhardt (JReinhardt@johnfreinhardt.com)
Peter Chin-Hong (phong@php.ucsf.edu)
Ellis Tobin (Ehtmd1@pol.net)
Daniel H. Kett (dkett@med.miami.edu)
Pinaki Biswas (Pinaki.Biswas@pfizer.com)
Robert Swanson (swansr1@pfizer.com)

Version: 5
Date: 8 January 2014

Author's response to reviews: see over
Shirish Huprikar  
*BMCMed Central*  
236 Gray’s Inn Road  
London WC1X 8HB  
UK  

January 2014  

Dear Dr Huprikar  

RE: Evaluation of an Early Step-Down Strategy from Intravenous Anidulafungin to Oral Azole Therapy for the Treatment of Candidemia and Other Forms of Invasive Candidiasis: Results from an Open-label Trial  

Following your letter of January 3, 2014, we have compiled a response and have revised the manuscript accordingly. My co-authors and I would be very grateful if you would again consider this manuscript for publication in *BMCMed Infectious Diseases.*  

We look forward to hearing from you.  

Yours faithfully  

Robert Swanson, PhD
<table>
<thead>
<tr>
<th>Comments</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Editor</strong></td>
<td><strong>Results, Page 13.</strong> The text has been modified as outlined below:</td>
</tr>
<tr>
<td>1. Regarding the revised statement below, were the susceptibilities not known or were actually resistant to fluconazole or voriconazole according to CLSI criteria?</td>
<td>'All baseline isolates were documented susceptible to the oral agents used except for three patients receiving oral fluconazole and four patients receiving oral voriconazole; there were no treatment failures in these cases. Three patients receiving oral fluconazole and four patients receiving oral voriconazole had baseline isolates which were resistant to fluconazole and voriconazole, respectively. There were no treatment failures among these seven patients. Baseline isolates from all other patients were documented susceptible to the oral agents used.'</td>
</tr>
</tbody>
</table>

"All baseline isolates were documented susceptible to the oral agents used except for three patients receiving oral fluconazole and four patients receiving oral voriconazole; there were no treatment failures in these cases."